Literature DB >> 30473130

Managing Toxicity of Intravesical Therapy.

Joachim Mathes1, Tilman Todenhöfer2.   

Abstract

Intravesical therapies have shown positive effects both on recurrence and progression of non-muscle-invasive bladder cancer. However, more than 50% of patients experience untoward side effects associated with treatment. In order to reduce the rate of patients who discontinue treatment due to side effects, prevention and effective management of treatment-related toxicity is essential.
Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BCG; Bladder cancer; Mitomycin; Side effects; Urothelial carcinoma

Mesh：

Substances：

Year:  2018        PMID： 30473130     DOI： 10.1016/j.euf.2018.09.009

Source DB:  PubMed          Journal:  Eur Urol Focus        ISSN： 2405-4569


  2 in total

1.  Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

Authors:  Bimal Bhindi; Ronald Kool; Girish S Kulkarni; D Robert Siemens; Armen G Aprikian; Rodney H Breau; Fadi Brimo; Adrian Fairey; Christopher French; Nawar Hanna; Jonathan I Izawa; Louis Lacombe; Victor McPherson; Ricardo A Rendon; Bobby Shayegan; Alan I So; Alexandre R Zlotta; Peter C Black; Wassim Kassouf
Journal:  Can Urol Assoc J       Date:  2021-08       Impact factor: 1.862

2.  Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer.

Authors:  Fabrizio Di Maida; Cristina Scalici Gesolfo; Riccardo Tellini; Andrea Mari; Chiara Sanfilippo; Luca Lambertini; Antonio Andrea Grosso; Marco Carini; Andrea Minervini; Vincenzo Serretta
Journal:  Ther Adv Urol       Date:  2021-02-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.